Vimarsana
Biggest News Aggregation in the World

Treatment Resistant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Treatment Resistant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Treatment Resistant Today - Breaking & Trending Today

Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD - Vimarsana News

Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD

The utility of second-generation antipsychotics and clozapine has been less advantageous than it could be, Kane explained.

AI could be used to identify suicidal behaviour: Dr Pratima Murthy, Director, NIMHANS - Vimarsana News

AI could be used to identify suicidal behaviour: Dr Pratima Murthy, Director, NIMHANS

A well-known name in addiction psychiatry, Dr Pratima has been instrumental in building the Centre for Addiction Medicine at NIMHANS.

MAC Breakfast will be March 28th - Vimarsana News

MAC Breakfast will be March 28th

The Geary County Convention Center will be the site for the Junction City Area Chamber of Commerce Military Affairs Council Breakfast on Mar

Source: jcpost.com
Clerkenwell Health's psychedelic drug trial seeks participants - Vimarsana News

Clerkenwell Health's psychedelic drug trial seeks participants

Some forms of depression cannot be cured by current treatments including antidepressants or going to psychological counselling or psychotherapy.

INmune Bio (NASDAQ:INMB) & Ignyte Acquisition (NASDAQ:IGNY) Financial Contrast - Vimarsana News

INmune Bio (NASDAQ:INMB) & Ignyte Acquisition (NASDAQ:IGNY) Financial Contrast

Ignyte Acquisition (NASDAQ:IGNY – Get Free Report) and INmune Bio (NASDAQ:INMB – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk. Analyst Ratings This is a summary of […]